Grünenthal to Acquire Bayer's Stivarga for up to €375M
Grünenthal agreed to acquire the oral cancer treatment Stivarga (regorafenib) from Bayer AG for up to €375 million, with closing expected by end of 2026 or early 2027.
Read the full coverage, free
We only link to sources you can read without a subscription. How we check.